Medullary thyroid carcinoma: Autologous tumor cell lines for dendritic cell vaccination

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 4225-4230

  Pfragner, Roswitha ^a   Skofitsch, Gerhard ^b   Höger, Harald ^c   Jech, Marion ^a   Rinner, Beate ^a   Siegl, Veronika ^a   Niederle, Bruno ^c   Gnant, Michael ^c   Friedl, Josef ^c   Stift, Anton ^c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Autologous tumor cell cultures; Dendritic cells; Drug resistance; Immunotherapy; Medullary thyroid carcinoma

Indexed keywords

CANCER VACCINE;

ARTICLE; AUTOTRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER SURGERY; CELL LYSATE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOLECULAR BIOLOGY; NEUROSECRETORY CELL; PHENOTYPE; PRIORITY JOURNAL; SURGICAL TECHNIQUE; THYROID MEDULLARY CARCINOMA; TUMOR CELL CULTURE;

ANIMALS; CANCER VACCINES; CARCINOMA, MEDULLARY; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; MICE, NUDE; THYROID NEOPLASMS;

EID: 27944469951     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ponder BA: The phenotypes associated with RET mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res 59: 1736-1741, 1999.
2. Donis-Keller H: The RET proto-oncogene and cancer. J Int Med 238: 318-325, 1995.
3. Donovan DT, Levy ML, Furst EJ, Alford BR, Wheeler T, Tschen JA and Gagel RF: Familial cutaneous lichen amyloidosis in association with multiple endocrine neoplasia type 2A: a new variant. Henry Ford Hosp Med J 37: 147-150, 1989.
4. Eng C and Mulligan LM: Mutations of the RET protooncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumors, and Hirschsprung disease. Hum Mutat 9: 97-109, 1991.
5. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moorem JK, Pap L, Ponder MA, Telenius H, Tunnacliffe A and Ponder BAJ: Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia syndrome type 2A. Nature (London) 363: 458-460, 1993.
6. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P and Lupoli G: Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 91: 1797-1808, 2001.
7. Yang KP, Liang YF and Samaan NA: Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: association with overexpression of mdrl gene and low proliferation fraction. Anticancer Res 11: 1065-1068, 1991.
8. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A and Schuler G: Generation of large numbers of fully mature and stable dendritic cells from leukopheresis products for clinical application. J Immunol Methods 224: 211, 1999.
9. Zitvogel L, Angevin E and Tursz T: Dendritic cell-based immunotherapy of cancer. Ann Oncol 11: 3199-3205, 2000.
10. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D and Schuler G: Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196: 137-151, 1996.
11. Gilboa E, Nair SK and Lyerly HK: Immunotherapy of cancer with dendritic-cell based vaccines. Cancer Immunol Immunother 46: 82-87, 1998.
12. Friedl J, Stift A, Paolini P, Roth E, Steger GG, Mader R, Jakesz R and Gnant MF: Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer. Cancer Biother Radiopharm 15: 477-486, 2000.
13. Nestle FO, Alijagic S, Gilliert M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
14. Holtl L, Zelle-Rieser C, Gander H, Papesch C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH Jr and Thurnher M: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous denritic cells. Clin Cancer Res 8: 3369-3376, 2002.
15. Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL and Murphy GP: Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40: 125-129, 1999.
16. Schott M, Feldkamp J, Schattenberg D, Seissler J and Scherbaum WA: Dendritic cell immunotherapy in disseminated parathyroid carcinoma. Lancet 353: 1188-1189, 1999.
17. Schott M, Feldkamp J, Schattenberg D, Krueger T, Dotzenrath C, Seissler J and Scherbaum WA: Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol 142: 300-306, 2000.
18. Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum WA and Feldkamp J: Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 86: 4965-4969, 2001.
19. Schott M, Feldkamp J, Lettmann M, Simon D, Scherbaum WA and Seissler J: Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma. Clin Endocrinol 55: 271-277, 2001.
20. Schott M, Feldkamp J, Klucken M, Kobbe G, Scherbaum WA and Seissler J: Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vacciniation. Cancer Immunol Immunother 51: 663-668, 2002.
21. Schott M and Seissler J: Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies. Trend Endocrinol Metab 14: 156-162, 2003.
22. Schott M, Scherbaum WA and Seissler J: Denditic cell-based immunotherapy in thyroid malignancies. Curr Drug Targets Immune Endocr Metabol Disord 4: 345-251, 2004.
23. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R and Gnant M: Dendritic cell-based vaccination in solid cancer. J Clin Oncol 1: 135-142, 2003.
24. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C, Jakesz R and Gnant M: In vitro induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells. Int J Oncol 22: 651-656, 2003.
25. Bachleitner-Hofmann T, Stift A, Friedl J, Pfragner R, Radelbauer K, Dubsky P, Schuller G, Benkoe R, Niederle B, Brostjan C, Jakesz R and Gnant M: Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells. J Clin Endocrinol Metab 87: 1098-1104, 2003.
26. Stift A, Sachet M, Yagubian R, Bittermann C, Dubsky P, Brostjan C, Pfragner R, Niederle B, Jakesz R, Gnant M and Friedl J: Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res 10: 2944-2953, 2004.
27. Leong SS, Horoszewicz JS, Shimaoka K, Friedman M, Kawinski E, Song MJ, Chu TM, Baylin S and Mirand EA: A new cell line for study of human medullary thyroid carcinoma. In: Andreoli M, Monaco H, Robbins J (eds.). Advances in Thyroid Neoplasia. Field Educational Itaila, Rome, pp. 95-108, 1981.
28. Carlomagno F, Salvatore D, Santoro M, de Franciscis V, Quadro L, Panariello L, Colantuoni V and Fusco A: Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 207: 1022-1028, 1995.
29. Pfragner R, Behmel A, Ingolic E and Wirnsberger H: Culture of human neuroendocrine tumor cells. In: Culture of Human Tumor Cells (Pfragner R and Freshney RI, eds.). Wiley-Liss, Hoboken, New Jersey, pp. 373-403, 2004.
30. Freshney RI: Tumor cells. In: Culture of Animal Cells. A Manual of Basic Techniques, 4th ed., Wiley-Liss, New York, pp. 385-393, 2000.
31. Dairkee SH, Paulo SC, Traquina P, Moore DH, Ljung BM and Smith HS: Partial enzymatic degradation of stroma allows enrichment and expansion of primary breast tumor cells. Cancer Res 57: 1590-1596, 1997.
32. Speirs V, Green AR, Walton DS, Kerin MJ, Fox JN, Carleton PJ, Desai SB and Atkin SL: Short-term primary culture of epithelial cells derived from human breast tumors. Br J Cancer 78: 1421-1429, 1998.
33. Holt SE, Wright WE and Shay JW: Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 16: 2932-2939, 1996.
34. Pfragner R, Höfler H, Behmel A, Ingolic E and Walser V: Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma. Cancer Res 50: 4160-4166, 1990.
35. Pfragner R, Wirnsberger G, Behmel A, Wolf G, Passath A, Ingolic E, Adamiker D and Schauenstein K: New continuous cell line from human medullary thyroid carcinoma: SINJ. Phenotypic analysis and in vivo carcinogenesis. Int J Oncol 2: 831-836, 1993.
36. Kaczirek K, Schindl M, Weinhäusel A, Scheuba C, Passler C, Prager G, Raderer M, Hamilton G, Mittlböck M, Siegl V, Pfragner R and Niederle B: Cytotoxic activity of camptotecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. J Clin Endocrin Metab 89: 2397-2401, 2004.